The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of bevacizumab and erlotinib in treatment-naive elderly patients (older than age 65) with advanced non-small cell lung cancer (NSCLC).
H. Borghaei
Consultant or Advisory Role - Genentech
Honoraria - Amgen; Genentech; Lilly
Research Funding - Genentech
R. Mehra
No relevant relationships to disclose
M. M. Millenson
No relevant relationships to disclose
H. Tuttle
No relevant relationships to disclose
K. Ruth
No relevant relationships to disclose
A. J. Magdalinski
No relevant relationships to disclose
D. M. Mintzer
Honoraria - Genentech
J. Lee
No relevant relationships to disclose
J. Stevenson
Honoraria - Genentech
Research Funding - Genentech
C. J. Langer
Consultant or Advisory Role - Genentech; OSI Pharmaceuticals
Research Funding - Genentech; OSI Pharmaceuticals